Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction-Reference-Cited by-同舟云学术

Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction

Published:2010-10 Issue:4 Volume:139 Page:1181-1189.e2
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Thompson Alexander J.,Fellay Jacques,Patel Keyur,Tillmann Hans L.,Naggie Susanna,Ge Dongliang,Urban Thomas J.,Shianna Kevin V.,Muir Andrew J.,Fried Michael W.,Afdhal Nezam H.,Goldstein David B.,McHutchison John G.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

3. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C;Fellay;Nature,2010

4. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency;Sumi;Hum Genet,2002

5. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population;Maeda;Mol Genet Metab,2005

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An ITPA Enzyme with Improved Substrate Selectivity;The Protein Journal;2023-12-08

2. Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study;Medicine;2023-10-27

3. Inosine triphosphate pyrophosphatase: A guardian of the cellular nucleotide pool and potential mediator of RNA function;WIREs RNA;2023-04-24

4. Integration of pharmacogenomic and pharmacomicrobiomic data for personalized medicine;Precision Medical Sciences;2023-03

5. Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients;International Journal of Molecular Sciences;2022-09-02